Clinical applications of expression profiling and proteomics in prostate cancer

Anticancer Research

Volumn 27, Issue 3 A, 2007, Pages 1273-1276

  Masters, John R W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Expression profiling; Marker; Prostate; Proteomics; Short review

Indexed keywords

MOLECULAR MARKER; RNA; TRANSCRIPTION FACTOR;

CONFERENCE PAPER; FUSION GENE; HISTOPATHOLOGY; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; SCREENING; UPREGULATION;

GENE EXPRESSION PROFILING; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEOMICS;

EID: 34249310626     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Chan JM, Jou RM and Carroll PR: The relative impact and future burden of prostate cancer in the United States. J Urol 172: S13-17, 2004.
2. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ and Haas GP: High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8: 439-443, 1994.
3. Albertsen PC, Hanley JA and Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-2101, 2005.
4. Chodak G: Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol 8(Suppl 2): S3-8, 2006.
5. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlen BJ and Johansson JE: Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977-1984, 2005.
6. Lytton B: Prostate cancer: a brief history and the discovery of hormonal ablation treatment. J Urol 165: 1859-1862, 2001.
7. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001.
8. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
9. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA and Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648, 2005.
10. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB and Chinnaiyan AM: TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66: 3396-3400, 2006.
11. Kallioniemi O: Functional genomics and transcriptomics of prostate cancer: promises and limitations. BJU Int 96(Suppl 2): 10-15, 2005.
12. Banez LL, Srivastava S and Moul JW: Proteomics in prostate cancer. Curr Opin Urol 15: 151-156, 2005.
13. Diamandis EP: Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res 66: 5540-5541, 2006.